Salute e Benessere
MacuMira and Keeler announce strategic partnership to expand Dry AMD therapy
"Keeler has a proud tradition of advancing eye care with uncompromising quality, craftsmanship and innovation in eyecare," said Andy Harbidge , Managing Director at Keeler. "This partnership marks a transformative moment as we align Keeler's heritage and reach with MacuMira's groundbreaking therapy. Together, we will bring new hope to patients and clinicians worldwide."
MacuMira's therapy is already established in Canada , where thousands of treatments have been delivered safely since early 2024. Clinical evidence, including a randomized controlled trial published in the , has demonstrated meaningful improvements in visual acuity and contrast sensitivity.
"This collaboration with Keeler accelerates our mission to change the trajectory of Dry AMD," said Justin Sather , CEO at MacuMira. "By combining Keeler's global presence with our novel science, we are redefining how this disease is managed, restoring not only vision but also dignity and independence to patients."
Caroline Atkins
Head of Global Marketing at Keeler
Email: marketing@keelerusa.com
Matt Van De Ven
COO at MacuMira Medical Devices Inc
Email: info@macumira.com
Founded in 1917, Keeler has built a legacy of innovation and quality in ophthalmic instruments. With a global presence and a commitment to transforming eye care, Keeler sets the standard for precision and reliability in clinical practice. Learn more at: www.keelerglobal.com
MacuMira is a Canadian medical device company dedicated to restoring vision and improving lives through retinal neurostimulation. With a strong clinical foundation and growing international presence, MacuMira is redefining how Dry AMD is managed worldwide. Learn more at: www.macumira.com
View original content:https://www.prnewswire.co.uk/news-releases/macumira-and-keeler-announce-strategic-partnership-to-expand-dry-amd-therapy-302590100.html